课题基金 / 基金详情

CORE--VECTOR DESIGN AND PRODUCTION

CORE--VECTOR DESIGN AND PRODUCTION
核心——矢量设计与制作
批准号:
6494881
负责人:
DAVID J. FINK
金额:
$38.25万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-03-01 至 2002-11-30

项目摘要

项目成果

DAVID J. FINK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The vector Design and Production Core will provide recombinant replication-incompetent herpes simplex virus (HSV)-based vectors to transfer and express selected transgenes in neurons in primary culture (Project 2) and in hippocampal neurons prior to and during ischemia in vivo (Project 3). This strategy will be used to directly test the role of selected known and novel genes, identified by their regional expression in ischemic brain (Project 1), in the regulation of ischemic neuronal death. HSV-based vectors will be constructed by homologous recombination of a plasmid-containing the selected gene under the control of the human cytomegalovirus immediate-early promoter (HCMV-IEp) and the lacZ reporter gene-into the thymidine kinase (tk) locus of an ICP4-replication- incompetent HSV vector propagated in complementing E5 cells. The expression of transgene RNA in vitro will be confirmed by Northern blot, and expression of the protein in vitro by Western blot. Gradient purified vector stocks will then be used to transfer and express the transgene product in vitro (Project 2) and in vivo (Project 3).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulatable Gene Expression for Prevention of Neuropathy
  • 批准号:
    8540668
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2013
  • 负责人:
    DAVID J. FINK
  • 依托单位:
Regulatable Gene Expression for Prevention of Neuropathy
  • 批准号:
    8966656
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2013
  • 负责人:
    DAVID J. FINK
  • 依托单位:
Preclinical Development of an NT3-expressing HSV Vector
Preclinical Development of an NT3-expressing HSV Vector
海外基金